Clear expectations for exported product, with more to come on the domestic market.
India’s current track and trace regulations pertain to products manufactured in India that will be exported to other markets. In June 2015 a draft proposal for domestic drugs was published, but no timelines have been established for the adoption of that set of serialization, labeling, and reporting regulations.
Barcoding and Serialization, Aggregation, and Reporting Highlights for Exported Products
Barcoding and Serialization: Uniquely serialize drug products at the tertiary (case), secondary (saleable unit), and mono-carton packaging levels. Barcoding and serialization requirements generally follow global GS1 standards while each packaging level requires that slightly different data be captured. For example, at the secondary pack level, the GTIN, batch number, expiration date and serial number must be captured and encoded in a 2D data matrix or at GS1-128 linear barcode.
Primary-level serialization – or serializing below the “each” level - is currently optional but is expected to become a firm requirement in the future. When it does, it will present a new set of challenges for pharmaceutical companies who will need to serialize, for instance, all of the blister cards within a saleable unit. This will likely raise issues around how packaging is done, what materials are used, where the 2D barcodes will be placed, and more.
Aggregation: Pharmaceutical companies must create aggregation relationships across all packaging hierarchies – including tertiary, secondary, and primary (if so encoded) - and maintain those relationships.
Reporting: India requires reporting on several events including product master data, batch pre-production and production/packaging actions. The pre-production notification alerts the DAVA portal of the intent to produce a batch and includes product code, lot number, and additional details.
When products are manufactured and packaged, product details, serialized identity across all required pack levels, and aggregation information must be captured and configured into XML reports which are then submitted to the India Drug Authentication and Verification Application (DAVA) portal.
Exemptions: The India Directorate General of Foreign Trade (DGFT) regulations on exported products do include an exemption that allows pharmaceutical companies to instead follow the serialization laws for their export market, if they exist. However, companies must still notify India about the products they are producing, to what market they are going, and to what other law you are complying that is prompting the exemption from the DGFT law.
A proven, purpose-built solution.
Six of the top 10 pharmaceutical companies in India rely on TraceLink for their export business. TraceLink provides a complete end-to-end India compliance solution for pharmaceutical companies and CMOs to meet the India compliance requirements for exported product. Master data management, serialization management, serialized operations management and compliance reporting modules are available on the cloud platform to support your business and your supply network. The India Compliance module is purpose-built for DAVA compliance. India Compliance delivers complete compliance data management, DAVA report generation and exception management, helping companies to reduce the time, cost, and risk associated with achieving compliance in India.